Found 58 matching trials
Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients PHASE3 The purpose of this study is to compare a standard chemotherapy regimen of ...
Show More Location
112 sites UK wide
Treatments Being Tested
Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance High dose melphalan therapy and autologous stem cell transplant (intensive pathway only) Learn More & Join Trial
Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years PHASE3 This protocol is an international, multicenter, comparative, open and rando...
Show More Location
Hospital Universitário Clementino Fraga Filho
Learn More & Join Trial
TCD Followed by autoSCT for Newly Diagnosed MM Patients PHASE2 Multiple Myeloma is a incurable disease. Thalidomide in combination with ot...
Show More Learn More & Join Trial
Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma PHASE4 Multicentric study, open, single arm, designed to evaluate the efficacy(res...
Show More Location
Hospital Morales Messeguer
Learn More & Join Trial
Velcade (Bortezomib) Consolidation After Transplant PHASE3 The purpose of this study is to determine if bortezomib when added to conso...
Show More Location
Multiple Locations
Learn More & Join Trial
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma PHASE2 RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some ...
Show More Location
Alta Bates Summit Comprehensive Cancer Center
Learn More & Join Trial
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy PHASE3 This study has been designed to evaluate whether "anti-angiogenesis" therap...
Show More Location
University of Arkansas for Medical Sciences/MIRT
Learn More & Join Trial
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation PHASE3 The best induction protocol to eligible multiple myeloma patients was not e...
Show More Location
CEHON - Centro de Hematologia e Oncologia da Bahia
Learn More & Join Trial
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation PHASE3 The purpose of this study is to find out if transplant with a new regimen o...
Show More Location
University of Arkansas for Medical Sciences/MIRT
Learn More & Join Trial
UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma PHASE2 The purpose of this study is to find out if treating multiple myeloma (MM) ...
Show More Location
University of Arkansas for Medical Sciences
Learn More & Join Trial